Analysis of therapeutic response onset time in thyroid cancer patients treated by lenvatinib

Analysis of therapeutic response onset time in thyroid cancer patients treated by lenvatinib - Analysis of therapeutic response onset time in thyroid cancer patients treated by lenvatinib

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000019484

Enrollment

Registered

2015-10-24

Start date

2015-10-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Thyroid cancer

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Thyroid cancer patients who treat by lenvatinib and can follow CT imagings regularly.

Exclusion criteria

Exclusion criteria: Thyroid cancer patients who treat by lenvatinib but can't follow CT imagings regularly.

Design outcomes

Primary

Measure	Time frame
Characterization of tumor size changes of 2,4,6,8,12,16,20 and 24 weeks after medication.	—

Secondary

Measure	Time frame
Improved response rate, time to first objective response, efficacy, changes of CT imaging, association with thyroglobulin, clinical factors of good responders.	—

Countries

Japan

Contacts

Public ContactChie Masaki

Ito Hospital Surgery

c-irikawa@ito-hospital.jp03-3402-7411

Outcome results